June 12 (Reuters) - Rallybio Corp RLYB.O:
RALLYBIO INITIATES DOSING IN RLYB116 PHASE 1 CONFIRMATORY PHARMACOKINETIC/PHARMACODYNAMIC STUDY
RALLYBIO CORP - DATA READOUTS EXPECTED FROM COHORT 1 IN 3Q 2025 AND COHORT 2 IN 4Q 2025
Source text: ID:nBw5dVb64a
Further company coverage: RLYB.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.